Showing 1 to 2 of 2 results


Proteomics Secures $4.5M to Launch Novel Diagnostic Blood Tests
Proteomics International Laboratories secured $4.5 million to launch three novel blood tests (PromarkerD, PromarkerEso, PromarkerEndo) across Australia and the US, aiming to address significant unmet needs in diabetic kidney disease, oesophageal cancer, and endometriosis diagnosis.
Proteomics Secures $4.5M to Launch Novel Diagnostic Blood Tests
Proteomics International Laboratories secured $4.5 million to launch three novel blood tests (PromarkerD, PromarkerEso, PromarkerEndo) across Australia and the US, aiming to address significant unmet needs in diabetic kidney disease, oesophageal cancer, and endometriosis diagnosis.
Progress
48% Bias Score

Proteomics International Secures \$2.16 Million R&D Rebate for Diagnostic Blood Tests
Proteomics International secured a \$2.16 million Australian R&D tax rebate to commercialize its innovative blood tests for diabetic kidney disease, endometriosis, and esophageal cancer, leveraging a \$4.95 million R&D investment and aiming for US market entry.

Proteomics International Secures \$2.16 Million R&D Rebate for Diagnostic Blood Tests
Proteomics International secured a \$2.16 million Australian R&D tax rebate to commercialize its innovative blood tests for diabetic kidney disease, endometriosis, and esophageal cancer, leveraging a \$4.95 million R&D investment and aiming for US market entry.
Progress
40% Bias Score
Showing 1 to 2 of 2 results